Skip to main content

抗真菌薬市場 to Reach $17.72 Billion by 2023 at 3.7% CAGR

According to the report, the global Antifungal Drugs market generated $14.23 billion in 2017 and is estimated to reach $17.72 billion by 2023, growing at a CAGR of 3.7% from 2017 to 2023. The report offers a detailed analysis of the key segments, top investment pockets, changing dynamics, market size & estimations, and competitive scenario.

Favorable government funds to combat the antifungal diseases along with the increasing prevalence of fungal infection drive the growth of the market. Furthermore, rising awareness levels pertaining to myriad fungal infections supplement the market growth. However, the growing population with antifungal drug resistance and the presence of counterfeit drugs and side effects of antifungal drugs restrict the growth. On the other hand, patent expirations and increasing funding from public & private organizations offer lucrative opportunities for the market.

Request Report Sample at: https://www.alliedmarketresearch.com/request-sample/2370

Based on drug types, the Azoles segment accounted for nearly two-fifths of the total market share in 2017 and is expected to maintain its dominance by 2023. Furthermore, this segment is estimated to project the fastest CAGR of 4.1% from 2017 to 2023.

Based on dosage form, the drugs segment held nearly one-third of the total market share in 2017 and will maintain its dominance throughout the forecast period. Furthermore, this segment is estimated to register the highest growth rate with a CAGR of 4.2% from 2017 to 2023.


Based on the region, Asia-Pacific would grow at the fastest CAGR of 4.5% from 2017 to 2023. However, the North America region contributed more than one-third of the total share in 2017 and is estimated to maintain its dominance during the forecast period. The report also includes the study of different regions such as Europe and LAMEA.

Based on therapeutic indication, Candidiasis segment held more than one-third of the total market share in 2017 and will maintain its dominance throughout the forecast period. However, the Dermatophytosis segment is estimated to register the highest growth rate with a CAGR of 4.1% from 2017 to 2023.

Do Purchase Enquiry at: https://www.alliedmarketresearch.com/purchase-enquiry/2370

The leading market players analyzed in the research include the GlaxoSmithKline Plc. Pfizer Inc., Enzon Pharmaceuticals, Inc., Sanofi S.A., Scynexis Inc., Gilead Sciences, Inc., Bayer AG, Merck & Co., Inc., Abbott Laboratories, and Novartis International AG. They have adopted different strategies such as mergers & acquisitions, partnerships, collaborations, new product launches, and others to gain a strong position in the global industry.

Labels:

Comments

Post a Comment

Popular posts from this blog

放射線情報システム市場 is expected to reach $941 million by 2022, supported by a CAGR of 5.9%

T he radiology information system market was valued at  $603 million  in 2015, and is projected to reach  $941 million  by 2022, growing at a CAGR of 5.9% from 2016 to 2022. The integrated radiology information systems segment held over three-fifths share of the total market in 2015. Radiology information system (RIS) is a computer networked system used to organize and manage the workflow of medical imagery and radiology department, supporting business analysis in a department. RIS is widely used along with picture archiving and communication system (PACS) and vendor neutral archive to manage billing, record keeping, and image archives. The integrated radiology information systems held the largest share in 2015 and is expected to grow at the highest CAGR of 6.0% during the analysis period. This is owing to the surging adoption and demand of integrated healthcare information technology platforms in various healthcare organization for easy operations to curb over expe...
Post a Comment
Read more

2027年までに9億8,330万ドルを獲得する心臓再同期療法市場

As per the report published by Allied Market Research, the   Cardiac Resynchronization Therapy Market   was pegged at $965.6 million in 2019, and is projected to reach $983.3 million by 2027, growing at a CAGR of 4.9% from 2020 to 2027. Download Sample Report at:  https://www.alliedmarketresearch.com/request-sample/10657 Rise in the geriatric population, increase in the prevalence of cardiovascular diseases, and development in healthcare infrastructure have boosted the growth of the U.S. cardiac resynchronization therapy market. Moreover, high-end technological developments in CRT devices supplemented the market growth. However, product recalls in the U.S., cost of CRT devices, and shortage of healthcare professionals hinder the market growth. On the contrary, developing opportunities in the low economic U.S. states would open lucrative opportunities for the market players. Covid-19 scenario- The integration of CRT pacemaker and cardiac resynchronization therapy defibrill...
Post a Comment
Read more

組織工学市場 to Reach $6.81 Billion by 2027: Allied Market Research

As per the report published by Allied Market Research, the global  Tissue Engineering Market  generated $2.37 billion in 2019, and is projected to garner $6.81 billion by 2027, growing at a CAGR of 14.2% from 2020 to 2027. Rise in need for tissue engineering in organ transplantation, surge in prevalence of chronic diseases and trauma emergencies, and advancements in medical equipment technologies drive the growth of the global tissue engineering market. However, high cost associated with tissue engineered products hampers the market growth. On the contrary, untapped opportunities in the developing markets is expected to create lucrative opportunities in the future. Download Detailed COVID-19 Impact Sample Report at:  https://www.alliedmarketresearch.com/request-for-customization/4323?reqfor=covid Covid-19 scenario: Since the Covid-19 outbreak, clinical research in tissue engineering is temporarily suspended and the funds are redirected for clinical trials for the Covid-1...
Post a Comment
Read more